Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomark Med ; 14(12): 1109-1119, 2020 08.
Article in English | MEDLINE | ID: mdl-32969251

ABSTRACT

Aim: To investigate the possible association between MMP-2 (-1575 G/A, -1306 C/T) and its inhibitor TIMP-2 (-418 G/C) functional polymorphisms with development of severity in systemic lupus erythematosus (SLE) patients. Materials & methods: 150 SLE patients and matched healthy controls were recruited. Polymorphisms were detected by PCR-RFLP and serum levels by ELISA. Results: Mean MMP-2 and TIMP-2 serum level and mRNA expression were significantly increased in SLE cases as compared with controls (p < 0.0001). The concomitant presence of both MMP-2 1575A and its inhibitor TIMP-2 418C alleles synergistically increased the risk of SLE by 3.25-fold (CI: 1.44-7.34, p = 0.003). Conclusion: MMP-2, TIMP-2 and MMP-2/TIMP-2 ratios may act as biomarkers for susceptibility to SLE.


Subject(s)
Genetic Predisposition to Disease , Lupus Erythematosus, Systemic/genetics , Matrix Metalloproteinase 2/genetics , Tissue Inhibitor of Metalloproteinase-2/genetics , Adolescent , Adult , Female , Gene Expression , Genetic Markers , Humans , Male , Matrix Metalloproteinase 2/blood , Polymorphism, Genetic , Severity of Illness Index , Tissue Inhibitor of Metalloproteinase-2/blood , Young Adult
2.
Biomark Med ; 13(1): 33-43, 2019 01.
Article in English | MEDLINE | ID: mdl-30561224

ABSTRACT

AIM: To investigate the possible association between MMP-9 (-1562 C/T) and TIMP-1 (372 T/C) polymorphism and inflammatory markers with disease activity in systemic lupus erythematosus (SLE) patients. MATERIALS & METHODS: 150 SLE patients were recruited. Disease severity was assessed by SLEDAI (SLE disease activity index). The polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and serum levels by ELISA. RESULTS: Among patients mean MMP-9 serum levels and mRNA expression were significantly decreased with increase in TIMP-1 levels (p < 0.0001). Concomitant presence of both MMP-9 1562 T and TIMP-1 372 C alleles synergistically increased risk of SLE by 7.89-fold (p < 0.0001). The mRNA expression of MMP-9 and TIMP-1 correlated with SLEDAI score. CONCLUSION: MMP-9, TIMP-1 and MMP-9/TIMP-1 ratios may act as biomarkers for susceptibility to SLE.


Subject(s)
Biomarkers/analysis , Lupus Erythematosus, Systemic/etiology , Matrix Metalloproteinase 9/genetics , Polymorphism, Single Nucleotide , Tissue Inhibitor of Metalloproteinase-1/genetics , Adult , Case-Control Studies , Female , Follow-Up Studies , Genetic Predisposition to Disease , Genotype , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/pathology , Male , Matrix Metalloproteinase 9/blood , Prognosis , Tissue Inhibitor of Metalloproteinase-1/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...